Healthcare Finance writes: Health systems are increasingly considering a boost to their price transparency efforts when it comes to order entry, but evidence for the effectiveness of this strategy has been spotty. New research published in the Journal of the American Medical Association Internal Medicine finds that displaying Medicare allowable fees for inpatient laboratory tests did not significantly change clinician ordering behavior, or the associated fees. The findings are significant because it’s been estimated that nearly 30 percent of laboratory testing in the United States may be wasteful.
- Healthcare Finance: http://www.healthcarefinancenews.com/news/price-transparency-inpatient-labratory-tests-has-little-effect-clinician-ordering-behavior-jama
- Effect of a Price Transparency Intervention in the Electronic Health Record on Clinician Ordering of Inpatient Laboratory Tests. The PRICE Randomized Clinical Trial. JAMA Internal Medicine. July 2017